NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company?s Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.